Revised SPC: Decapeptylâ„¢ (triptorelin) SR 3mg/11.25mg/22.5mg

Publisher:
Glenmark Pharmaceuticals Europe Ltd
Publication date:
21 May 2014

Abstract

?Section 4.2 now states that in patients treated with GnRH analogues for metastatic prostate cancer, treatment is usually continued upon development of castrate-resistant prostate cancer. Reference should be made to relevant guidelines.